James Altman, MD
Interventional Cardiology · Sumter, SCNPI 1194928457
Payments from drug & device makers
Across 316 payments — averaging $31.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$2K
- Novartis$1K
- Shockwave Medical, Inc$663
- Amgen$574
- Pfizer$571
- plus $3K from 21 others
What the payments were for
- Travel & lodging$1,69317%
- Food & beverage$8,09183%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 42 | $2,207 |
| Abbott | 10 | $1,513 |
| Novartis | 70 | $1,428 |
| Shockwave Medical, Inc | 6 | $663 |
| Amgen | 34 | $574 |
| Pfizer | 31 | $571 |
| AstraZeneca | 14 | $543 |
| Boston Scientific | 16 | $538 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $395 |
| E.r. Squibb & Sons, L.L.C. | 23 | $279 |
| Johnson & Johnson | 9 | $131 |
| Edwards Lifesciences | 1 | $103 |
| Merck | 6 | $101 |
| Boehringer Ingelheim | 6 | $98 |
| Alnylam Pharmaceuticals Inc. | 4 | $87 |
| Atricure, Inc. | 3 | $82 |
| Novo Nordisk | 3 | $77 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $74 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $57 |
| Scpharmaceuticals Inc. | 3 | $50 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Lundbeck LLC | 2 | $31 |
| Bayer | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $23 |
| Philips North America LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,401
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$542
- Micra$532
- LINQ II$297
- ENTRESTO$249
- AZURE XT DR MRI SURESCAN$158
- OMNIASECURE MRI SURESCAN$156
- COBALT DR MRI SURESCAN$155
- RESOLUTE ONYX$122
- WATCHMAN Access System$118
- Edwards SAPIEN 3 Transcatheter Heart Valve$103
- Watchman$102
How this compares
$9,798 in reported general payments places this provider in the 45th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 274 | $292,550 |
| Repatha SureclickEvolocumab | 122 | $98,514 |
| XareltoRivaroxaban | 48 | $62,039 |
| EntrestoSacubitril/Valsartan | 32 | $36,237 |
| BrilintaTicagrelor | 59 | $36,189 |
| Rosuvastatin Calcium | 353 | $11,108 |
| JardianceEmpagliflozin | 14 | $9,580 |
| VascepaIcosapent Ethyl | 13 | $7,930 |
| Metoprolol Succinate | 416 | $7,595 |
| Atorvastatin Calcium | 385 | $6,015 |
| Carvedilol | 527 | $5,553 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 101 | $3,678 |
| Losartan Potassium | 213 | $3,214 |
| Telmisartan | 55 | $3,086 |
| Icosapent Ethyl | 11 | $2,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $571 | $292,550274 claims |
| Johnson & JohnsonXarelto | $131 | $62,03948 claims |
| NovartisEntresto | $1,428 | $36,23732 claims |
| AstraZenecaBrilinta | $543 | $36,18959 claims |
| Boehringer IngelheimJardiance | $98 | $9,58014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Sumter
- Vishal DhulipalaSumter$17K
- Daniel SteinbergCharleston$1.1M
- Nicholas AmorosoPawleys Island$1.1M
- Robert LeonardiWest Columbia$881K
- Lars RunquistCharleston$861K
- Kurt BarringhausColumbia$536K
- Brian BrownSpartanburg$477K
- Josh DollGreenville$429K
- Thomas TodoranPawleys Island$316K
- Daniel GreenGreenville$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.